Debio 0228 is a radioligand development program targeting the CAIX (Carbonic Anhydrase 9) enzyme to fight the tumor progression via internal radiation. The program, currently in Lead Optimization stage, is set to identify a Development Candidate with best-in-class potential within the 177Lu-CAIX radiopharmaceutical peptidomimetic class.
The compound is being developed as a monotherapy to treat patients whose tumors express the CAIX target. The selected compound will be developed with the emerging theranostic approach, which combines diagnostic and therapeutic features with the same compound. Specific diagnostic molecular imaging will allow the pre-identification of patients who have the CAIX receptors necessary to respond to the targeted radiotherapy.
March 25, 2020
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy